Mechanisms of KE298, 2-acetylthiomethyl-3-(4-methylbenzoyl) propionic acid, to suppress abnormal synovial cell functions in patients with rheumatoid arthritis.

@article{Sakane1997MechanismsOK,
  title={Mechanisms of KE298, 2-acetylthiomethyl-3-(4-methylbenzoyl) propionic acid, to suppress abnormal synovial cell functions in patients with rheumatoid arthritis.},
  author={Tsuyoshi Sakane and Noboru Suzuki and Yuichi Hirose and Keisuke Miura and Sueshige Wakisaka and Hiroko Nagafuchi and Motohide Ichino and Tetsuya Tomita and Hiroshi Hashimoto and Takahiro Ochi and Shoji Mihara},
  journal={The Journal of rheumatology},
  year={1997},
  volume={24 11},
  pages={2213-20}
}
OBJECTIVE 2-Acetylthiomethyl-3-(4-methylbenzoyl) propionic acid, KE298, a derivative or propionic acid developed in Japan has been shown to be effective for suppressing disease activity of rheumatoid arthritis (RA) in clinical trials in Japan. It is thus a candidate as a new disease modifying antirheumatic drug (DMARD). We analyzed effects of KE298 on synovial fibroblast-like cells in patients with RA to obtain insight into the clinical application of this medication. METHODS RA synovial… CONTINUE READING